The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control
Status and phase
Conditions
Treatments
Details and patient eligibility
About
The purpose of this study is to determine if magnesium can improve blood pressure, cholesterol, and blood sugar control in patients with implantable cardioverter defibrillators (ICDs).
Full description
Magnesium is the second most abundant intracellular cation and plays a vital role in many physiologic processes. It has been determined that patients with cardiovascular disease have intracellular magnesium (Mgi) deficiencies. Among the ICD registries in Europe and the United States 64% and 77% of patients also carry the diagnosis of CAD, respectively. Patients with CAD have risk factors that lead to the development and or propagation of atherosclerosis. Paramount among these risk factors are hypertension, dyslipidemia, and diabetes.
Comparison: Magnesium compared to placebo in patients with ICDs to evaluate the effect they have on cholesterol, blood pressure, and blood glucose.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Newly implanted ICD or recent ICD shock (within 6 months)
Exclusion criteria
- Inability to swallow
- A non-cardiac disease with a survival prognosis of less than 12 months
- Hypermagnesemia
- Creatinine clearance less than 30mL/min
- Lactic acidosis or systemic acidosis syndrome
- Previous intolerance to magnesium L-lactate
Trial design
Primary purpose
Allocation
Interventional model
Masking
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal